AI-assisted support for DORA Article 30 ICT contract reviews. In development for single-tenant hosting in Germany, with no external AI API calls at runtime and human review before any finding is final.
For financial entities within DORA's scope, ICT service contracts need the relevant Article 30 provisions. Reviewers must connect contractual wording with applicable requirements and document their decisions. FLAIRONEX is being developed to support that evidence-based review.
In development: AI-assisted review of ICT vendor contracts against applicable DORA Article 30 requirements. Intended output: draft findings linked to contract evidence and regulatory references, for human review.
Designed for single-tenant hosting in Germany and local model inference, with no external AI API calls at runtime. Hosting location, model dependencies and operational access are separate considerations.
Planned workflow: contract evidence, draft findings, human review, an approved report and a vendor letter. Your team decides applicability and any follow-up action.
Initial scope: German and English ICT vendor contracts in PDF. Document support and extraction quality are being validated.
Planned review of applicable DORA Article 30 requirements, with applicability confirmed by a human reviewer. Designed to produce structured output traceable to contract evidence, processed on servers in Germany.
Planned draft findings with DORA references, contract evidence and suggested remediation. Human review is required before findings are final.
Planned review history linking evidence, findings and human approvals. End-to-end audit-trail functionality remains in development.
Designed for hosting on Hetzner infrastructure in Germany, with no US hyperscaler in the runtime data path. Hosting location alone does not establish complete technological or jurisdictional sovereignty.
Designed so that model weights reside on the same disk as the database and inference traffic never leaves the host.
Designed to link draft findings to contract evidence and regulatory references. Human reviewers determine applicability and approve findings. Compliance support, not legal advice.
MVP planned for October 2026. Flaironex is currently in research and development phase. Leave your email to receive a non-binding notification when the product is ready for evaluation.